Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.

ABSTRACT: Immunotherapy is a new pillar of cancer therapy that provides novel opportunities to treat solid tumors. In this context, the development of new drugs targeting immune checkpoints is considered a promising approach in colorectal cancer (CRC) treatment because it can be induce specific and durable anti-cancer effects. Despite many advances in the immunotherapy of CRC, there are still limitations and obstacles to successful treatment. The immunosuppressive function of the tumor microenvironment (TME) is one of the causes of poor response to treatment in CRC patients. For this reason, checkpoint-blocking antibodies have shown promising outcomes in CRC patients by blocking inhibitory immune checkpoints and enhancing immune responses against tumors. This review summarizes recent advances in imm

SUBMITTER: Makaremi S 

PROVIDER: S-EPMC8467932 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature